Series A3 September 2020

uMotif secures £5m Series A investment led by AlbionVC to expand clinical trial software

The financing round will accelerate product development and international growth for the patient data capture platform.

£5.0MSeries A

uMotif provides a patient-centric data capture software platform designed for clinical studies and research. The company works with pharmaceutical and biotech organisations to facilitate decentralised and virtual trials.

London-based software company uMotif has secured £5m in a Series A funding round to support its expansion in the clinical trials sector. The investment was led by existing backer AlbionVC, with participation from DNV GL and angel investors.

The capital will be used to enhance the company platform, drive commercial growth, and enable international expansion into new study types. The funding arrives as life sciences companies increasingly adopt decentralised study designs following shifts in the healthcare sector.

The firm offers cloud-based software that allows participants to share research data from their own devices. Its technology is currently utilised across multiple countries and therapeutic areas by leading pharmaceutical developers.

From the founder

Bruce Hellman
CEO and Co-Founder at uMotif

Investor perspective

"Now more than ever, having access to reliable patient data during clinical trials is crucial. uMotif’s platform is built with patients in mind; designed to help academics, researchers and healthcare professionals to capture the best quality data in a way that suits the participants. It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the speed and efficiency with which therapies can reach and help millions of patients."

Andrew Elder

Deputy Managing Partner, AlbionVC